Samsung Biologics acquires PolyPeptide Group
Analysis based on 30 articles · First reported Jul 19, 2026 · Last updated Jul 20, 2026
The acquisition positions Samsung Biologics — Samsung Biologics America to capture growth in the peptide CDMO market, especially for GLP-1 obesity drugs, which could reach $150 billion by 2035. Samsung Biologics — Samsung Biologics America' stock fell up to 3.3% on the announcement, reflecting concerns over the premium paid, but the long-term strategic benefits may offset short-term dilution.
Samsung Biologics — Samsung Biologics America, a South Korean contract drug manufacturer, has launched an all-cash public tender offer to acquire PolyPeptide Group, a Swiss peptide CDMO, for approximately CHF 1.46 billion ($1.8 billion). The offer price of CHF 44.31 per share represents a 40% premium to PolyPeptide's unaffected closing price before acquisition rumors emerged. The transaction is expected to close by the end of 2026, subject to shareholder acceptance, regulatory approvals, and other conditions. PolyPeptide's board unanimously recommends the offer, and its largest shareholder, Draupnir Holding (55.65% stake), has irrevocably agreed to tender its shares. The acquisition expands Samsung Biologics — Samsung Biologics America into peptide-based active pharmaceutical ingredients, particularly GLP-1 drugs for obesity and diabetes, and adds manufacturing facilities in Europe, the US, and India. Samsung Biologics — Samsung Biologics America plans to delist PolyPeptide from the SIX Swiss Exchange and operate it as a wholly owned subsidiary. JPMorgan Chase is serving as exclusive financial adviser, with Ernst & Young, O Melveny & Myers, and Schellenberg Wittmer providing other advisory services. The deal is the largest M&A in South Korea's biopharmaceutical sector.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard